178 related articles for article (PubMed ID: 27440830)
1. New Long-Acting Basal Insulins: Does Benefit Outweigh Cost?
Standl E; Owen DR
Diabetes Care; 2016 Aug; 39 Suppl 2():S172-9. PubMed ID: 27440830
[No Abstract] [Full Text] [Related]
2. Newer insulins in type 2 diabetes.
Gale EA
BMJ; 2012 Sep; 345():e4611. PubMed ID: 22968720
[No Abstract] [Full Text] [Related]
3. Long-acting insulin analogs versus human insulins.
Garg SK; Naik RG
Diabetes Technol Ther; 2008 Oct; 10(5):331-2. PubMed ID: 18715208
[No Abstract] [Full Text] [Related]
4. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of basal insulins: A review.
Vargas-Uricoechea H; Aschner P
Diabetes Metab Syndr; 2021; 15(6):102318. PubMed ID: 34695771
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility of albiglutide versus insulin lispro, insulin glargine, and sitagliptin for the treatment of type 2 diabetes in the US.
Bruhn D; Martin AA; Tavares R; Hunt B; Pollock RF
J Med Econ; 2016 Jul; 19(7):672-83. PubMed ID: 26882484
[TBL] [Abstract][Full Text] [Related]
7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
8. A patient centred approach to basal insulin choice for the management of type 2 diabetes mellitus.
Kalra S; Gupta Y
J Pak Med Assoc; 2016 Mar; 66(3):360-1. PubMed ID: 26968297
[TBL] [Abstract][Full Text] [Related]
9. Using 2nd generation basal insulins in type 2 diabetes: Costs and savings in a comparative economic analysis in Italy, based on the BRIGHT study.
Napoli R; Fanelli F; Gazzi L; Larosa M; Bitonti R; Furneri G
Nutr Metab Cardiovasc Dis; 2020 Oct; 30(11):1937-1944. PubMed ID: 32912786
[TBL] [Abstract][Full Text] [Related]
10. Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for type 2 diabetes: meta-analysis of randomized controlled trials.
Esposito K; Chiodini P; Capuano A; Petrizzo M; Improta MR; Giugliano D
Diabetes Care; 2012 Dec; 35(12):2698-705. PubMed ID: 23173139
[TBL] [Abstract][Full Text] [Related]
11. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
[TBL] [Abstract][Full Text] [Related]
12. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
[TBL] [Abstract][Full Text] [Related]
13. Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US.
Dempsey M; Mocarski M; Langer J; Hunt B
J Med Econ; 2018 Nov; 21(11):1110-1118. PubMed ID: 30114954
[TBL] [Abstract][Full Text] [Related]
14. [Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study].
Bierwirth RA; Kohlmann T; Moock J; Holle R; Landgraf W
Med Klin (Munich); 2010 Nov; 105(11):792-801. PubMed ID: 21136237
[TBL] [Abstract][Full Text] [Related]
15. A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.
Idris I; Gordon J; Tilling C; Vora J
J Med Econ; 2015 Apr; 18(4):273-82. PubMed ID: 25422990
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of insulin detemir versus insulin glargine for Thai type 2 diabetes from a payer's perspective.
Permsuwan U; Thavorn K; Dilokthornsakul P; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Sep; 20(9):991-999. PubMed ID: 28649943
[TBL] [Abstract][Full Text] [Related]
17. Glycemic control with insulin glargine plus insulin glulisine versus premixed insulin analogues in real-world practices: a cost-effectiveness study with a randomized pragmatic trial design.
Levin PA; Zhang Q; Mersey JH; Lee FY; Bromberger LA; Bhushan M; Bhushan R
Clin Ther; 2011 Jul; 33(7):841-50. PubMed ID: 21719107
[TBL] [Abstract][Full Text] [Related]
18. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
[TBL] [Abstract][Full Text] [Related]
19. Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary.
Reynolds LR
Postgrad Med; 2010 Jan; 122(1):201-3. PubMed ID: 20107306
[TBL] [Abstract][Full Text] [Related]
20. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis.
Guillermin AL; Samyshkin Y; Wright D; Nguyen T; Villeneuve J
J Med Econ; 2011; 14(2):207-16. PubMed ID: 21361858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
